Bruker faced a tough 2024, with aggressive M&A, $600M preferred issuance, rising debt, and execution issues prompting a ...
In recent days, AbCellera and Bruker resolved their global patent dispute, with Bruker agreeing to pay US$36 million upfront plus ongoing royalties on Beacon Optofluidic platform sales. At the same ...
Investors may be wondering whether Bruker is quietly turning into a value opportunity, or if the recent noise is just a distraction from deeper issues in the business. The stock has bounced 6.8% over ...
Detailed price information for Abcellera Biologics Inc (ABCL-Q) from The Globe and Mail including charting and trades.
Bruker Corporation (Nasdaq: BRKR) today announced several significant European orders for high-performance magnetic resonance ...
Investor's Business Daily on MSN
Stocks to watch: Bruker sees relative strength rating jump to 81
On Monday, Bruker BRKR reached a key technical benchmark, with its Relative Strength (RS) Rating rising into the 80-plus ...
RI Research Instruments, a company that is majority-owned by Bruker Corporation (Nasdaq: BRKR), today announced orders for key components and enabling subsystems for the research gamma ray source of ...
Fintel reports that on December 15, 2025, B of A Securities maintained coverage of Bruker (NasdaqGS:BRKR) with a Buy ...
Shareholders of Bruker Corp (Symbol: BRKR) looking to boost their income beyond the stock's 0.4% annualized dividend yield can sell the December 2026 covered call at the $60 strike and collect the ...
AbCellera has reached a settlement and patent-license agreement to resolve patent litigation with Bruker Corporation. The biotechnology company said Thursday that it will receive a $36 million payment ...
Bruker (BRKR) stock in focus as Wolfe Research upgrades the company on a robust 2026 EPS growth, margin expansion, and revenue growth. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback